SecBot SecBot

ONC

BeOne Medicines Ltd.
Nasdaq· Pharmaceutical Preparations· CIK 0001651308 Biotech & Drug Discovery
$411.29 −5.25 (−1.26%)
Nov 16 4:00 PM ET · prev $416.54
Market cap
$47.5B
Large cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$468.62
+14% · range $400.00–561.30
1 year
+9.2%
from $376.63 · Nov 17
30 days
+11.1%
from $370.17
52-week range
$260.27–424.00
−3% from high · low Jun 11
Avg volume 20D
452.7K
shares / day
Short interest
1.60M
≈1.4% of shares · −10.6%
Days to cover
4.4
at average volume
Insider net
−$47.9M
0 buyers · 3 sellers · since Sep 8
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
27
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 8 neutral oldest → newest, height = score
Avg score ·High conf. 8/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $47.9M.

  • InstitutionsBULLISH

    Q2 2026: 30 added (3 new), 16 trimmed or exited. Largest new: Qube Research & Technologies $23.2M, Life Cycle Investment Partners $20.8M.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Median target $468.62 (+14%).

  • Short sellersSTEADY

    Short interest −10.6% to 1.60M shares. 4.4 days to cover, ≈1.4% of shares.

  • TrendUPTREND

    11% above its 50-day average. New closing high $424.00 on Nov 10.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$59.4M
in new stakes
FundMoveSharesValue
FMR LLCTRIM2,478,527$706.3M
Capital World InvestorsADD2,249,582$641.1M
CITADEL ADVISORS LLCADD1,425,517$406.2M
PRICE T ROWE ASSOCIATES INC /MD/ADD758,752$216.2M
MILLENNIUM MANAGEMENT LLCDOUBLED543,323$154.8M
Man Group plcADD307,463$87.6M
UBS Group AGTRIM258,589$73.7M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED249,758$71.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy3Buy7Hold1Sell0Strong Sell0
12-month targets · 27 analysts

Price is inside the target range. Median implies +14%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 6, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 6, 2026Truist Securities
REITERATE
REITERATEBuy
Nov 6, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 6, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Nov 6, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$47.9M
sold · 3 insiders
DateInsiderTypeValue
Nov 9, 2026
Wang Xiaodong
Director
Nov 9, 2026
GIFT1,183 sh
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
EXERCISE$182.6K
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
EXERCISE$108.0K
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
EXERCISE8,827 sh
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
SELL$621.7K
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
SELL$10.6K
Nov 6, 2026
Ball Titus B.
Principal Accounting Officer
Nov 6, 2026
EXERCISE11,440 sh
Nov 5, 2026
Lee Chan Henry
SVP, General Counsel
Nov 5, 2026
SELL$182.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

9 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
1,602,619
shares short
-10.6%
vs prior settlement
4.4
days to cover
≈1.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
CEO John Oyler filed an amended Schedule 13G reporting beneficial ownership of 54,065,077 ordinary shares (3.6% of…
SC 13G/A · Impact 2/10
Nov 10, 2026 SEC
Two BeOne Medicines insiders sold a combined $805K in open-market sales within a week of the company's strong Q3…
CLUSTER · Impact 3/10
Nov 9, 2026 Insider
Wang Xiaodong gifted 1,183 shares
Director
Nov 6, 2026 SEC
Titus B. Ball, an officer of BeOne Medicines Ltd., filed a Form 144 notice of intent to sell 1,559 ADSs with an…
144 · Impact 2/10
Nov 6, 2026 Insider
Ball Titus B. acquired via exercise 880 shares
Principal Accounting Officer @ $207.55 ($182.6K)
Nov 6, 2026 Insider
Ball Titus B. acquired via exercise 679 shares
Principal Accounting Officer @ $159.03 ($108.0K)
Oct 18, 2026 Clinical trial readout
T-90d Trial Readout: Zanubrutinib (Phase 3)
Trial: A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Mal
Jun 30, 2026 Inst.
FMR LLC · TRIM
2,478,527 shares ($706.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

27 filings · 3 bullish · 4 bearish · 1 mixed · 19 neutral
All ONC filing & press-release reports (27)